Watch Live

Tweet TWEET

Actelion Pharmaceuticals Ltd : Actelion to present at the 31st Annual J.P. Morgan Healthcare Conference - Delivering on our

  Actelion Pharmaceuticals Ltd : Actelion to present at the 31st Annual J.P.
          Morgan Healthcare Conference - Delivering on our strategy

Actelion Pharmaceuticals Ltd / Actelion to present at the 31st Annual J.P.
Morgan Healthcare Conference - Delivering on our strategy . Processed and
transmitted by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND  -  07 January  2013-  Actelion Ltd  (SIX:  ATLN) 
Actelion Ltd (SIX: ATLN)  announced today that  Jean-Paul Clozel, M.D.,  Chief 
Executive Officer of  Actelion, will present  at the J.  P. Morgan  Healthcare 
Conference on Tuesday, 08 January 2013 at  9.30 a.m. Pacific time / 18.30  hrs 
Swiss time at the Westin St. Francis Hotel in San Francisco, CA.

Dr. Clozel will describe  the progress made during  2012 in delivering on  the 
three elements of Actelion's strategy for value creation.

1) Sustain and grow the PAH franchise

Dr. Clozel will present an overview of Actelion's current product offerings in
the pulmonary arterial hypertension  (PAH) market. He  will also describe  the 
excellent morbidity  / mortality  outcome data  from the  SERAPHIN study  with 
macitentan (Opsumit®). This novel and differentiated dual endothelin  receptor 
antagonist (ERA)  was the  result  of a  tailored  drug discovery  process  in 
Actelion's labs.

In addition,  Dr.  Clozel will  describe  the opportunity  for  the  Company's 
selective IP  receptor agonist,  selexipag -  developed together  with  Nippon 
Shinyaku - which has now enrolled over 1,000 patients into GRIPHON, a  pivotal 
study  also   designed   to  demonstrate   a   reduction  in   the   risk   of 
morbidity/mortality events.

Dr. Clozel will present how Actelion's  franchise today and in the future  has 
the potential to reshape the treatment paradigm in PAH.

2) Build an additional specialty franchise

Dr.  Clozel  will  also  present  the  positive  results  with  the  Company's 
innovative compounds,  ponesimod in  psoriasis  and cadazolid  in  Clostridium 
difficile associated diarrhea. At the end of 2012, mid-stage clinical  studies 
reported results that allowed Actelion to  decide to pursue both compounds  in 
Phase III  development. This  provides Actelion  with the  foundation for  its 
mid-term goal of building an additional specialty franchise.

3) Optimize profitability

As the  third element  to Actelion's  strategy, the  company is  committed  to 
profit growth in the coming years and to value creation for shareholders.  Dr. 
Clozel will present the  measures taken to ensure  the company can deliver  on 
these commitments and the company's near and mid-term core earnings guidance.

Jean-Paul Clozel, MD and  Chief Executive Officer  of Actelion commented:  "At 
last year's J. P. Morgan conference I told the audience that 2012 would be  an 
important year for  Actelion. I am  very pleased to  take this opportunity  to 
describe the  excellent  progress the  company  has  made to  deliver  on  our 
strategy for value  creation. In 2013,  and the years  to come, Actelion  will 
realize the value it has created from innovation in our labs."

The presentation is available in pdf-format on www.actelion.com. To access the
live and subsequently archived webcast of the presentation, visit "Events"  in 
the Investor Relations  section of Actelion's  corporate website. An  archived 
replay will  be available  for 3  months  beginning 24  hours after  the  live 
presentation.

                                     ###

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland.  Actelion's  first drug  Tracleer®,  an  orally 
available dual endothelin receptor antagonist, has been approved as a  therapy 
for pulmonary arterial hypertension.  Actelion markets Tracleer® through  its 
own subsidiaries in key markets worldwide, including the United States  (based 
in South  San Francisco),  the European  Union, Japan,  Canada, Australia  and 
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to  the endothelium  - the  single layer  of cells  separating 
every blood vessel  from the  blood stream. Actelion's  over 2,400  employees 
focus on  the discovery,  development and  marketing of  innovative drugs  for 
significant unmet medical needs. Actelion shares  are traded on the SIX  Swiss 
Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss
Market Index SMI®).



For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com



The above information contains certain "forward-looking statements",  relating 
to  the  company's  business,   which  can  be  identified   by  the  use   of 
forward-looking terminology such as "estimates","believes", "expects", "may",
"are  expected   to",  "will",   "will   continue",  "should",   "would   be", 
"seeks","pending" or "anticipates" or similar expressions, or by  discussions 
of strategy, plans or intentions. Such statements include descriptions of  the 
company's investment  and research  and development  programs and  anticipated 
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect  the 
current views of the company with respect to future events and are subject  to 
certain risks, uncertainties  and assumptions.  Many factors  could cause  the 
actual results, performance or  achievements of the  company to be  materially 
different from any future  results, performances or  achievements that may  be 
expressed or implied by such forward-looking statements. Should one or more of
these risks  or uncertainties  materialize, or  should underlying  assumptions 
prove incorrect,  actual  results may  vary  materially from  those  described 
herein as anticipated, believed, estimated or expected.

Press Release PDF

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1668485

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;